Multiple myeloma is a cancer of the plasma cells found in bone marrow and it constitutes 1 percent of total cancer incidence worldwide. The disease is responsible for 2 percent of total cancer-related deaths worldwide.
CBD/THC is known to decrease mitochondrial membrane potential and induced apoptosis by activating caspases 8, caspase 3 and poly (ADP-ribose) polymerase. In addition, the combination of CBD and THC increased the expression level of beclin-1 and light chain 3-II form proteins indicating activation of autophagy.
OWC conducted pre-clinical studies on multiple myeloma (MM) cell lines and CD138+ MM cells isolated from patients at a leading academic medical center in Israel. These studies showed that the combination of CBD/THC at certain ratios had synergistic cytotoxic activity on these cell lines. This combined effect of the compounds was significantly higher compared to CBD or THC alone.
Furthermore, the combination of CBD/THC together with bortezomib, carfilzomib, dexamethasone and doxorubicin increased MM cell death significantly as compared to each of these drugs or CBD/THC alone.
OWC’s newly developed highly concentrated formulation (OWC-1808) was administered in vivo in an animal model for the first time and was found to be safe and tolerable. This formulation will allow the delivery of very high doses of CBD and THC with exceptional bioavailability. The continued development and testing of this formulation is directed initially at our ongoing program for treating Multiple Myeloma.